Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVeris licenses chlamydia vaccine candidate
BioVeris entered into a license agreement with the University of Massachusetts Amherst (UMA) for rights to commercialize products for possible use in the prevention, diagnosis and treatment of
BioVeris entered into a license agreement with the University of Massachusetts Amherst (UMA) for rights to commercialize products for possible use in the prevention, diagnosis and treatment of
The companies will work together to discover, develop and commercialize novel therapies targeted against the liver X receptor (LXR), a nuclear hormone receptor thought to play a role
RapidFire lead discovery is a mass spectrometry-based technology that enables the high throughput screening of biochemical assays. The use of mass spectrometry allows for label-free screening of challenging
PTC124 is a novel, orally administered drug that targets nonsense mutations and is being investigated initially as a treatment for cystic fibrosis (CF) and Duchenne muscular dystrophy, with
This license will expand Accentia’s pipeline of innovative products for respiratory diseases and enable Accentia to enter the large intranasal steroid market. Collegium plans to file a supplemental
Cephalon will acquire all of the outstanding share capital of Zeneus Holdings for approximately $360 million in cash. The transaction is expected to close no later than early
Under the agreement, Novartis has obtained worldwide licensing rights to investigational agent AT9311, an Astex cell cycle inhibitor that is currently completing preclinical studies. Novartis also has an
The collaborators aim to discover a range of novel domain antibodies (dAbs) to address therapeutic targets involved in T-cell co-stimulation, some of which may not be amenable to
Under the agreement, Antares will apply its advanced transdermal delivery (ATD) gel platform to create a new, branded pharmaceutical product. Antares will recognize R&D revenue from this work,
Evotec has granted Takeda exclusive rights to a novel target in Alzheimer’s disease, based on successful target identification and validation work, triggering a milestone payment of a few